Announced that it has extended its drug discovery and advancement collaboration with Allergan today.

The research term of the collaboration has now been extended by the parties for an additional year through March 2012. ACADIA also offers two other collaboration agreements with Allergan, which have resulted in current clinical programs in the regions of chronic pain and glaucoma. Related StoriesScientists suggest that Alzheimer's disease ought to be treated separatelyEnvisia's ENV515 meets major efficacy endpoint in stage 2a glaucoma trialAllergan enters into contract to acquire Aquesys and its XEN45 program We are delighted to increase our longstanding scientific collaboration with Allergan, an acknowledged head in the field of eye care, said Uli Hacksell, Ph.D., CEO of ACADIA.It offers many collection advantages, and samples could be easier analyzed using highly delicate enzyme immunoassays and LC-MS/MS instrumentation. Agilent's updated oral fluid compendium, Drugs and Metabolites in Oral Fluid: Immunoassay Screening and LC/MS/MS Confirmation and Quantification, is a thorough treatise on the recognition of drugs of misuse in oral fluid, covering 100 medications in 11 classes. The compendium includes info on sample preparation and collection, immunoassay screening and LC/QQQ confirmation. In addition, it reflects changes to the mandatory guidelines for Federal Place of work Drug Testing Programs, possesses protocols for all your newly recommended Timetable II prescription medications. Agilent created the compendium in collaboration with Immunalysis Corp..